DEC TIMOTHY C 4

What Happened

• Timothy C. Dec, Senior Vice President & Chief Financial Officer of Supernus Pharmaceuticals (SUPN), had 2,500 restricted stock units (RSUs) settle on Feb 25, 2026. The company withheld 1,279 shares to satisfy tax withholding obligations at an implied value of $50.69 per share (total ≈ $64,833), leaving a net delivery of 1,221 shares to Mr. Dec.

Key Details

• Transaction date: 2026-02-25; Filing date: 2026-02-26 (timely filing).
• Items reported: A (award/acquisition) of 2,500 RSUs; F (tax withholding) of 1,279 shares at $50.69 per share (≈ $64,833); D (settlement/disposition relating to the derivative RSUs).
• Net shares delivered to insider: 2,500 − 1,279 = 1,221 shares (based on reported withholding).
• Footnotes: F1 — shares were withheld to satisfy tax withholding; F2 — each RSU equals one share on vesting; F3 — these RSUs are part of a grant that vests in four equal annual installments beginning Feb 23, 2024.
• Shares owned after the transaction are not reported in the excerpt provided.

Context

• This was not an open-market sale or purchase by the insider; it was the settlement of RSUs and routine tax withholding (a common administrative step when equity grants vest). Such transactions are standard and do not by themselves indicate a change in the insider’s view of company prospects.